nanotech investing Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib ) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial 08 September
nanotech investing Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference 02 September
nanotech investing Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress 10 August
